Neurotech International
Market Cap
AU$558.9k
Last Updated
2020/04/05 10:46 UTC
Data Sources
Company Financials
Executive Summary
Neurotech International Limited engages in the research, design, development, and manufacture of medical devices and solutions in Australia.
Snowflake Analysis
Weak fundamentals or lack of information.
Share Price & News
How has Neurotech International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NTI's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
33.3%
NTI
12.0%
AU Medical Equipment
5.1%
AU Market
1 Year Return
-60.0%
NTI
12.0%
AU Medical Equipment
-19.0%
AU Market
Return vs Industry: NTI underperformed the Australian Medical Equipment industry which returned 12% over the past year.
Return vs Market: NTI underperformed the Australian Market which returned -19.2% over the past year.
Shareholder returns
| NTI | Industry | Market | |
|---|---|---|---|
| 7 Day | 33.3% | 12.0% | 5.1% |
| 30 Day | -42.9% | -12.8% | -20.9% |
| 90 Day | -76.5% | -16.3% | -25.6% |
| 1 Year | -60.0%-60.0% | 14.1%12.0% | -15.4%-19.0% |
| 3 Year | -98.6%-98.7% | 30.2%24.0% | -3.3%-16.6% |
| 5 Year | n/a | 71.6%56.9% | 6.9%-17.3% |
Price Volatility Vs. Market
How volatile is Neurotech International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
What Kind Of Shareholder Appears On The Neurotech International Limited's (ASX:NTI) Shareholder Register?1 month ago | Simply Wall St
Did Neurotech International Limited (ASX:NTI) Insiders Sell Shares?2 months ago | Simply Wall St
Those Who Purchased Neurotech International (ASX:NTI) Shares Three Years Ago Have A 95% Loss To Show For ItValuation
Is Neurotech International undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Neurotech International is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Neurotech International has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Next Steps
- Take a look at our analysis of NTI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Neurotech International regulatory filings.
- Explore potentially undervalued companies in the Healthcare industry.
Future Growth
How is Neurotech International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
39.2%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Neurotech International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Take a look at our analysis of NTI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Neurotech International competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has Neurotech International performed over the past 5 years?
-13.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NTI is currently unprofitable.
Growing Profit Margin: NTI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NTI is unprofitable, and losses have increased over the past 5 years at a rate of -13.1% per year.
Accelerating Growth: Unable to compare NTI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NTI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.7%).
Return on Equity
High ROE: NTI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Next Steps
Financial Health
How is Neurotech International's financial position?
Financial Position Analysis
Short Term Liabilities: NTI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: NTI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: NTI has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: NTI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Inventory Level: NTI has a low level of unsold assets or inventory.
Debt Coverage by Assets: NTI has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NTI has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: NTI has less than a year of cash runway if free cash flow continues to grow at historical rates of 6.3% each year.
Next Steps
Dividend
What is Neurotech International's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate NTI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NTI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NTI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NTI's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.4yrs
Average management tenure
CEO
Peter James Griffiths (55yo)
1.42s
Tenure
AU$316,067
Compensation
Mr. Peter James Lawrence Griffiths, B.Sc. (Hons), has been the Chief Executive Officer and Managing Director at Neurotech International Limited since November 26, 2018. Mr. Griffiths a Senior Advisor at Br ...
CEO Compensation Analysis
Compensation vs Market: Peter James's total compensation ($USD189.93K) is about average for companies of similar size in the Australian market ($USD238.58K).
Compensation vs Earnings: Peter James's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Deputy Chairman | 1.42yrs | AU$316.07k | 5.22% A$29.2k | |
| Chief Scientific Officer & Member of Scientific Advisory Board | no data | no data | no data | |
| Company Secretary | 1yr | no data | no data |
1.4yrs
Average Tenure
Experienced Management: NTI's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Deputy Chairman | 1.42yrs | AU$316.07k | 5.22% A$29.2k | |
| Chief Scientific Officer & Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data | |
| Independent Non-Executive Director | 1yr | AU$8.45k | 0.24% A$1.4k | |
| Independent Non-Executive Chairman | 1yr | AU$10.83k | no data | |
| Chairman of Scientific Advisory Board & Non-Executive Director | no data | AU$69.67k | 0.10% A$571.4 | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data |
1.3yrs
Average Tenure
Experienced Board: NTI's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.4%.
Top Shareholders
Company Information
Neurotech International Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Neurotech International Limited
- Ticker: NTI
- Exchange: ASX
- Founded: 2016
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$558.926k
- Shares outstanding: 139.73m
- Website: https://www.neurotechinternational.com
Location
- Neurotech International Limited
- 145 Stirling Highway
- Suite 5 CPC
- Nedlands
- Western Australia
- 6009
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| NTI | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Nov 2016 |
| NTI | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Nov 2016 |
| NTIL.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Nov 2016 |
Biography
Neurotech International Limited engages in the research, design, development, and manufacture of medical devices and solutions in Australia. Its product, Mente Autism, is a portable electroencephalogram medical device that uses neurofeedback to help relax the minds of children with autism spectrum disorder. The company focuses on developing neuro-stimulation and neuro-diagnostic solutions that enable medical practitioners to monitor and play an active role in home-based therapies. It also engages in executing medical research projects and developing technological devices; and publishing, registering, and maintaining intellectual property. The company was incorporated in 2016 and is based in Nedlands, Australia.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/04/05 10:46 |
| End of Day Share Price | 2020/04/03 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.